Professor James Cassidy

  • Visiting Professor (Institute of Cancer Sciences)

email: James.Cassidy@glasgow.ac.uk

Cruk, Coap, Alexander Stone Building, Glasgow G61 1BD

Publications

List by: Type | Date

Jump to: 2019 | 2018 | 2017 | 2016 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001
Number of items: 123.

2019

Iveson, T. et al. (2019) 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT. Health Technology Assessment, 23(64), (doi: 10.3310/hta23640) (PMID:31852579)

2018

Robles-Zurita, J. A. et al. (2018) SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer. British Journal of Cancer, 119(11), pp. 1332-1338. (doi: 10.1038/s41416-018-0319-z) (PMID:30420616) (PMCID:PMC6265336)

Iveson, T. J. et al. (2018) 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. Lancet Oncology, 19(4), pp. 562-578. (doi: 10.1016/S1470-2045(18)30093-7) (PMID:29611518) (PMCID:PMC5883334)

2017

Graham, J., Spiliopoulou, P., Arbuckle, R., Bridge, J. A. and Cassidy, J. (2017) A pilot study of subjective well-being in colorectal cancer patients and their caregivers. Patient Related Outcome Measures, 8, pp. 111-119. (doi: 10.2147/PROM.S141815) (PMID:29089790) (PMCID:PMC5656346)

2016

O’Neill, H.L., Cassidy, A.P., Harris, O.B. and Cassidy, J.W. (2016) BMP2/BMPR1A is linked to tumour progression in dedifferentiated liposarcomas. PeerJ, 4, e1957. (doi: 10.7717/peerj.1957) (PMID:27114889) (PMCID:PMC4841227)

2014

Hickish, T. et al. (2014) A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer. European Journal of Cancer, 50(18), pp. 3136-3144. (doi: 10.1016/j.ejca.2014.08.008) (PMID:25441408)

Chu, E., Haller, D., Cartwright, T., Twelves, C., Cassidy, J., Sun, W., Saif, M.W., McKenna, E., Lee, S. and Schmoll, H.-J. (2014) Epidemiology and natural history of central venous access device use and infusion pump function in the NO16966 trial. British Journal of Cancer, 110(6), pp. 1438-1445. (doi: 10.1038/bjc.2014.74)

2013

Glen, H. and Cassidy, J. (2013) Phase I Trials in Oncology: Design and Endpoint. In: Rudek, M. A., Chau, C. H., Figg, W. D. and McLeod, H. L. (eds.) Handbook of Anticancer Pharmacokinetics and Pharmacodynamics [2nd ed.]. Series: Cancer drug discovery and development. Springer, pp. 99-105. ISBN 9781461491347 (doi:10.1007/978-1-4614-9135-4_6)

2012

Steele, N., Anthony, A., Saunders, M., Esmarck, B., Ehrnrooth, E., Kristjansen, P.E.G., Nihlén, A., Hansen, L.T. and Cassidy, J. (2012) A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer. British Journal of Cancer, 106(5), pp. 793-798. (doi: 10.1038/bjc.2011.599)

Graham, J.S. and Cassidy, J. (2012) Adjuvant therapy in colon cancer. Expert Review of Anticancer Therapy, 12(1), pp. 99-109. (doi: 10.1586/era.11.189)

Samol, J., Ranson, M., Scott, E., Macpherson, E., Carmichael, J., Thomas, A. and Cassidy, J. (2012) Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study. Investigational New Drugs, 30(4), pp. 1493-1500. (doi: 10.1007/s10637-011-9682-9)

2011

Paul, J. , Iveson, T., Midgely, R., Harkin, A., Masterton, M., Alexander, L. and Cassidy, J. (2011) Choice of randomisation time-point in non-inferiority studies of reduced treatment duration: experience from the SCOT study. Trials, 12(Sup.1), A30. (doi: 10.1186/1745-6215-12-S1-A30)

Cassidy, J. (2011) Guidelines for adjuvant therapy in colorectal cancer. Are they useful? And to whom? Clinical Oncology, 23(5), pp. 312-313. (doi: 10.1016/j.clon.2010.06.001)

Miles, D., Harbeck, N., Escudier, B., Hurwitz, H., Saltz, L., Van Cutsem, E., Cassidy, J., Mueller, B. and Sirzen, F. (2011) Disease Course Patterns After Discontinuation of Bevacizumab: Pooled Analysis of Randomized Phase III Trials. Journal of Clinical Oncology, 29(1), pp. 83-88. (doi: 10.1200/JCO.2010.30.2794)

Boyd, K.A. , Briggs, A. , Paul, J. , Iveson, T., Midgely, R., Harkin, A., Bates, G., Alexander, L. and Cassidy, J. (2011) Analysis of adverse events and quality of life data for an economic evaluation of adjuvant chemotherapy in colorectal cancer: when can we stop collecting? Trials, 12, A41. (doi: 10.1186/1745-6215-12-S1-A41)

Cassidy, J., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Rittweger, K., Gilberg, F. and Saltz, L. (2011) XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. British Journal of Cancer, 105(1), pp. 58-64. (doi: 10.1038/bjc.2011.201)

Cassidy, J., Saltz, L., Twelves, C., Van Cutsem, E., Hoff, P., Kang, Y., Saini, J.P., Gilberg, F. and Cunningham, D. (2011) Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients. Annals of Oncology, 22(12), pp. 2604-2609. (doi: 10.1093/annonc/mdr031)

Graham, J., Cassidy, J., Hughes, D. and Duerden, M. (2011) Ring-fencing a budget for cancer drugs: is it fair? Journal of the Royal College of Physicians of Edinburgh, 41(3), pp. 224-228. (doi: 10.4997/JRCPE.2011.310)

Lindsay, C.R. and Cassidy, J. (2011) XELOX in colorectal cancer: a convenient option for the future? Expert Review of Gastroenterology and Hepatology, 5(1), pp. 9-19. (doi: 10.1586/egh.10.90)

Yip, N. C., Fombon, I. S., Liu, P., Brown, S., Kannappan, V., Armesilla, A. L., Xu, B., Cassidy, J., Darling, J. L. and Wang, W. (2011) Disulfiram modulated ROS–MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties. British Journal of Cancer, 104(10), pp. 1564-1574. (doi: 10.1038/bjc.2011.126)

2010

Douillard, J.-Y. et al. (2010) Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study. Journal of Clinical Oncology, 28(31), pp. 4697-4705. (doi: 10.1200/JCO.2009.27.4860)

Xu, B., Guo, X., Mathew, S., Armesilla, A. L., Cassidy, J., Darling, J. L. and Wang, W. (2010) Triptolide simultaneously induces reactive oxygen species, inhibits NF-κB activity and sensitizes 5-fluorouracil in colorectal cancer cell lines. Cancer Letters, 291(2), pp. 200-208. (doi: 10.1016/j.canlet.2009.10.013)

Cassidy, J., Saltz, L. B., Giantonio, B. J., Kabbinavar, F. F., Hurwitz, H. I. and Rohr, U.-P. (2010) Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. Journal of Cancer Research and Clinical Oncology, 136(5), pp. 737-743. (doi: 10.1007/s00432-009-0712-3)

2009

Walker, J., Cassidy, J. and Sharpe, M. (2009) The third Symptom Management Research Trial in Oncology (SMaRT Oncology-3): a randomised trial to determine the efficacy of adding a complex intervention for major depressive disorder (Depression Care for People with Lung Cancer) to usual care, compared to usual care alone in patients with lung cancer. Trials, 10(1), p. 92. (doi: 10.1186/1745-6215-10-92)

Okines, A., del Puerto, O., Cunningham, D., Chau, I., Van Cutsem, E., Saltz, L. and Cassidy, J. (2009) Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. British Journal of Cancer, 101(7), pp. 1033-1038. (doi: 10.1038/sj.bjc.6605259)

Scott, L., Evans, T., Cassidy, J., Harden, S., Paul, J., Ullah, R., O'Brien, V. and Brown, R. (2009) Cytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour response. British Journal of Cancer, 101(3), pp. 410-417. (doi: 10.1038/sj.bjc.6605175)

Seymour, L. et al. (2009) Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. International Journal of Oncology, 34(6), pp. 1629-1636. (doi: 10.3892/ijo_00000293)

Lindsay, C.R., MacPherson, I.R.J. and Cassidy, J. (2009) Current status of cediranib: the rapid development of a novel anti-angiogenic therapy. Future Oncology, 5(4), pp. 421-432. (doi: 10.2217/FON.09.18)

Hénin, E. et al. (2009) A Dynamic Model of Hand-and-Foot Syndrome in Patients Receiving Capecitabine. Clinical Pharmacology and Therapeutics, 85(4), pp. 418-425. (doi: 10.1038/clpt.2008.220)

Cunningham, D. et al. (2009) Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. Annals of Oncology, 20(2), pp. 244-250. (doi: 10.1093/annonc/mdn638)

Walker, J., Cassidy, J. and Sharpe, M. (2009) The second Symptom Management Research Trial in Oncology (SMaRT Oncology-2): a randomised trial to determine the effectiveness and cost-effectiveness of adding a complex intervention for major depressive disorder to usual care for cancer patients. Trials, 10, p. 18. (doi: 10.1186/1745-6215-10-18)

2008

Arkenau, H.-T. et al. (2008) Efficacy of Oxaliplatin Plus Capecitabine or Infusional Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Randomized Trials. Journal of Clinical Oncology, 26(36), pp. 5910-5917. (doi: 10.1200/JCO.2008.16.7759)

Graham, J., Plummer, R., Mccoy, C., Kowal, K., Wiesinger, H., Detjen, K., Calvert, H., Wiedenmann, B. and Cassidy, J. (2008) Open-label, non-randomised, inter-individual dose escalation of ZK 304709 with the evaluation of safety, tolerability, pharmacokinetics, oral bioavailability and orientating efficacy after daily administration in patients with advanced cancer (7 d treatment and 14 d recovery). European Journal of Cancer, 44(15), pp. 2162-2168. (doi: 10.1016/j.ejca.2008.06.006)

Cassidy, J. (2008) Radio-chemotherapy in rectal cancer. European Journal of Cancer, 44(12), pp. 1620-1621. (doi: 10.1016/j.ejca.2008.06.002)

Cassidy, J. (2008) Cetuximab for the treatment of patients with colorectal cancer. Nature Clinical Practice Oncology, 5(6), pp. 310-311. (doi: 10.1038/ncponc1130)

Cassidy, J., Schmoll, H. and Van Cutsem, E. (2008) Pharmacoeconomic benefits of capecitabine-based chemotherapy in metastatic colorectal cancer. Journal of Clinical Oncology, 26(13), pp. 226-227. (doi: 10.1200/JCO.2008.16.4244)

Haller, D. G. et al. (2008) Potential Regional Differences for the Tolerability Profiles of Fluoropyrimidines. Journal of Clinical Oncology, 26(13), pp. 2118-2123. (doi: 10.1200/JCO.2007.15.2090)

Glen, H. and Cassidy, J. (2008) Redefining adjuvant chemotherapy in patients with stage III colon cancer: X-ACT trial. Expert Review of Anticancer Therapy, 8(4), pp. 547-551. (doi: 10.1586/14737140.8.4.547)

Saltz, L. B. et al. (2008) Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study. Journal of Clinical Oncology, 26(12), pp. 2013-2019. (doi: 10.1200/JCO.2007.14.9930)

Cassidy, J. et al. (2008) Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer. Journal of Clinical Oncology, 26(12), pp. 2006-2012. (doi: 10.1200/JCO.2007.14.9898)

Sharp, L., Little, J., Brockton, N., Cotton, S., Masson, L., Haites, N. and Cassidy, J. (2008) Polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene, intakes of folate and related B vitamins and colorectal cancer: a case-control study in a population with relatively low folate intake. British Journal of Nutrition, 99(2), pp. 379-389. (doi: 10.1017/S0007114507801073)

Espie, C., Fleming, L., Cassidy, J., Samuel, L., Taylor, L., White, C., Douglas, N., Engleman, H., Kelly, H. and Paul, J. (2008) Randomized controlled clinical effectiveness trial of cognitive behavior therapy compared with treatment as usual for persistent insomnia in patients with cancer. Journal of Clinical Oncology, 26(28), pp. 4651-4658. (doi: 10.1200/JCO.2007.13.9006)

Guo, X., Goessl, E., Collie-Duguid, E., Cassidy, J., Wang, W. and O'Brien, V. (2008) Cell cycle perturbation and acquired 5-fluorouracil chemoresistance. Anticancer Research, 28(1A), pp. 9-14.

MacPherson, I. and Cassidy, J. (2008) Challenges in combinational oncology studies. Pharmaceutical Medicine, 22(2), pp. 85-97.

2007

Cassidy, J. (2007) Capecitabine plus oxaliplatin in metastatic colorectal cancer. Journal of Clinical Oncology, 25(31), pp. 5043-5045. (doi: 10.1200/JCO.2007.13.4676)

Guo, X., Evans, T.R.J. , Somanath, S., Armesilla, A.L., Darling, J.L., Schatzlein, A., Cassidy, J. and Wang, W. (2007) In vitro evaluation of cancer-specific NF-kappaB-CEA enhancer-promoter system for 5-fluorouracil prodrug gene therapy in colon cancer cell lines. British Journal of Cancer, 97(6), pp. 745-754. (doi: 10.1038/sj.bjc.6603930)

MacLeod, A., Branch, A., Cassidy, J., McDonald, A., Mohammed, N. and Macdonald, L. (2007) A nurse-/pharmacy-led capecitabine clinic for colorectal cancer: results of a prospective audit and retrospective survey of patient experiences. European Journal of Oncology Nursing, 11(3), pp. 247-254. (doi: 10.1016/j.ejon.2006.10.001)

Kelly, C. and Cassidy, J. (2007) Capecitabine in the treatment of colorectal cancer. Expert Review of Anticancer Therapy, 7(6), pp. 803-810. (doi: 10.1586/14737140.7.6.803)

Wang, W., McLeod, H., Cassidy, J. and Collie-Duguid, E. (2007) Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks. Cancer Chemotherapy and Pharmacology, 59(6), pp. 839-845. (doi: 10.1007/s00280-006-0384-5)

Cassidy, J. (2007) Which first-line treatment is superior in advanced colorectal cancer: XELOX or pviFOX? Nature Clinical Practice Oncology, 4(5), pp. 280-281. (doi: 10.1038/ncponc0792)

Kelly, C. and Cassidy, J. (2007) Chemotherapy in metastatic colorectal cancer. Surgical Oncology, 16(1), pp. 65-70. (doi: 10.1016/j.suronc.2007.04.006)

Benson, C. et al. (2007) A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. British Journal of Cancer, 96(1), pp. 29-37. (doi: 10.1038/sj.bjc.6603509)

Hanauske, A., Cassidy, J., Sastre, J., Bolling, C., Jones, R. , Rakhit, A., Fettner, S., Brennscheidt, U., Feyereislova, A. and Diaz-Rubio, E. (2007) Phase 1b dose escalation study of erlotinib in combination with infusional 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors. Clinical Cancer Research, 13(2), pp. 523-531. (doi: 10.1158/1078-0432.CCR-06-1627)

Barrett, S.V. and Cassidy, J. (2007) Conventional chemotherapeutics. In: Alison, M.R. (ed.) The Cancer Handbook. John Wiley & Sons Ltd: Chichester, pp. 1191-1198. ISBN 9780470018521

Cassidy, J. (2007) Is breast cancer advocacy distorting the cancer budget to the disadvantage of other tumours? Breast Cancer Research, 9(Suppl.), S6. (doi: 10.1186/bcr1804)

Cassidy, J. (2007) Why patient representation might harm science? Breast Cancer Research, 9(Suppl.), S4. (doi: 10.1186/bcr1802)

2006

Cassidy, J. (2006) The bottom line. European Journal of Cancer, 42(17), p. 2859.

Cassidy, J. (2006) Did you skip the lectures? European Journal of Cancer, 42(17), pp. 2860-2867. (doi: 10.1016/j.ejca.2006.07.010)

Cassidy, J. (2006) In response to: 'On prejudice and facts and choices', an editorial by Kohne and Folprecht. Annals of Oncology, 17(9), pp. 1469-1471. (doi: 10.1093/annonc/mdl082)

Robinson, H., Jones, R., Walker, M., Zachos, G., Brown, R., Cassidy, J. and Gillespie, D. (2006) Chk1-dependent slowing of S-phase progression protects DT40 B-lymphoma cells against killing by the nucleoside analogue 5-fluorouracil. Oncogene, 25(39), pp. 5359-5369. (doi: 10.1038/sj.onc.1209532)

Paul, J. , Briggs, A. , Harking, A., Hayclon, M., Iveson, T., Masterson, M., Midgley, A. and Cassidy, J. (2006) SCOT: short course oncology therapy — a comparison of 12 and 24 weeks of adjuvant chemotherapy in colorectal cancer. In: 2011 ASCO Annual Meeting, Chicago, Ill, USA, 3-7 Jun 2011, e14145.

Cassidy, J. et al. (2006) Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. British Journal of Cancer, 94(8), pp. 1122-1129. (doi: 10.1038/sj.bjc.6603059)

Chong, G. et al. (2006) Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer. Annals of Oncology, 17(3), pp. 437-442. (doi: 10.1093/annonc/mdj090)

Glen, H. and Cassidy, J. (2006) Vitamin D (and its analogs) in the treatment and prevention of cancer. Expert Review of Anticancer Therapy, 6(3), pp. 305-308. (doi: 10.1586/14737140.6.3.305)

Rustin, G. et al. (2006) Comparison of CA-125 and Standard Definitions of Progression of Ovarian Cancer in the Intergroup Trial of Cisplatin and Paclitaxel Versus Cisplatin and Cyclophosphamide. Journal of Clinical Oncology, 24(1), pp. 45-51. (doi: 10.1200/jco.2005.01.2757)

Cassidy, J., Bissett, D., Spence, R.A.J. and Payne, M. (Eds.) (2006) Oxford Handbook of Oncology. Series: Oxford medical publications. Oxford University Press: Oxford, UK. ISBN 9780198567875

Cassidy, J., Johnston, P.G. and Van Cutsem, E. (2006) Colorectal Cancer. Taylor & Francis: Atlanta. ISBN 9780824728359

2005

Nikolic-Tomasevic, Z., Jelic, S., Cassidy, J., Filipovic-Ljeskovic, I. and Tomasevic, Z. (2005) Fluoropyrimidine therapy: hyperbilirubinemia as a consequence of hemolysis. Cancer Chemotherapy and Pharmacology, 56(6), pp. 594-602. (doi: 10.1007/s00280-005-1011-6)

Boddy, A. et al. (2005) A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules. Clinical Cancer Research, 11(21), pp. 7834-7840. (doi: 10.1158/1078-0432.CCR-05-0803)

Beutel, G., Glen, H., Schoffski, P., Chick, J., Gill, S., Cassidy, J. and Twelves, C. (2005) Phase I study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors. Clinical Cancer Research, 11(15), pp. 5487-5495. (doi: 10.1158/1078-0432.CCR-05-0104)

Camidge, R., Reigner, B., Cassidy, J., Grange, S., Abt, M., Weidekamm, E. and Jodrell, D. (2005) Significant Effect of Capecitabine on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Cancer. Journal of Clinical Oncology, 23(21), pp. 4719-4725. (doi: 10.1200/JCO.2005.09.129)

Twelves, C. et al. (2005) Capecitabine/Oxaliplatin, a Safe and Active First-Line Regimen for Older Patients with Metastatic Colorectal Cancer: Post Hoc Analysis of a Large Phase II Study. Clinical Colorectal Cancer, 5(2), pp. 101-107. (doi: 10.3816/CCC.2005.n.021)

Twelves, C. et al. (2005) Capecitabine as adjuvant treatment for stage III colon cancer. New England Journal of Medicine, 352(26), pp. 2696-2704. (doi: 10.1056/NEJMoa043116)

Nurgat, Z., Craig, W., Campbell, N., Bissett, J., Cassidy, J. and Nicolson, M. (2005) Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy. British Journal of Cancer, 92(6), pp. 1001-1005. (doi: 10.1038/sj.bjc.6602423)

Mano, M., Cassidy, J. and Canney, P. (2005) Liver metastases from breast cancer: management of patients with significant liver dysfunction. Cancer Treatment Reviews, 31(1), pp. 35-48. (doi: 10.1016/j.ctrv.2004.09.007)

Eatock, M., Cassidy, J., Johnson, J., Morrison, R., Devlin, M., Blackey, R., Owen, S., Choi, R. and Twelves, C. (2005) A dose finding and pharmacokinetic study of the matrix metalloproteinase inhibitor MM1270 (previously termed CGS27023A) with 5-FU and folinic acid. Cancer Chemotherapy and Pharmacology, 55(1), pp. 39-46. (doi: 10.1007/s00280-004-0856-4)

Cassidy, J. (2005) Benefits and drawbacks of the use of oral fluoropyrimidines as single-agent therapy in advanced colorectal cancer. Clinical Colorectal Cancer, 5(Suppl), S47-S50. (doi: 10.3816/CCC.2005.s.007)

Cassidy, J. (2005) Drug development and study design. In: Schellens, J.H.M., McLeod, H.L. and Newell, D.R. (eds.) Cancer Clinical Pharmacology. Oxford University Press: Oxford, UK, pp. 41-50. ISBN 9780192629661

Waterston, A. and Cassidy, J. (2005) Adjuvant treatment strategies for early colon cancer. Drugs, 65(14), pp. 1935-1947. (doi: 10.2165/00003495-200565140-00003)

2004

Rooney, P., Boonsong, A., McFadyen, M., McLeod, H., Cassidy, J., Curran, S. and Murray, G. (2004) The candidate oncogene ZNF217 is frequently amplified in colon cancer. Journal of Pathology, 204(3), pp. 282-288. (doi: 10.1002/path.1632)

Cassidy, J. and Schõtzlein, A. (2004) Tumour targeted drug and gene delivery: principles and concepts. Expert Reviews in Molecular Medicine, 6(19), pp. 1-17. (doi: 10.1017/S1462399404008269)

Bissett, D. et al. (2004) Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT). British Journal of Cancer, 91(1), pp. 50-55. (doi: 10.1038/sj.bjc.6601922)

Salazar, R., Bissett, D., Twelves, C., Breimer, L., Demario, M., Campbell, S., Zhi, J., Ritland, S. and Cassidy, J. (2004) A phase I clinical and pharmacokinetic study of Ro 31-7453 given as a 7- or 14-day oral twice daily schedule every 4 weeks in patients with solid tumors. Clinical Cancer Research, 10(13), pp. 4374-4382. (doi: 10.1158/1078-0432.CCR-04-0135)

Cassidy, J. et al. (2004) XELOX (capecitabine plus oxaliplatin): Active first-line therapy for patients with metastatic colorectal cancer. Journal of Clinical Oncology, 22(11), pp. 2084-2091. (doi: 10.1200/JCO.2004.11.069)

Robertson, R., Campbell, N., Smith, S., Donnan, P., Sullivan, F., Duffy, R., Ritchie, L., Millar, D., Cassidy, J. and Munro, A. (2004) Factors influencing time from presentation to treatment of colorectal and breast cancer in urban and rural areas. British Journal of Cancer, 90(8), pp. 1479-1485. (doi: 10.1038/sj.bjc.6601753)

Gourley, C., Cassidy, J., Edwards, C., Samuel, L., Bisset, D., Camboni, G., Young, A., Boyle, D. and Jodrell, D. (2004) A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer. Cancer Chemotherapy and Pharmacology, 53(2), pp. 95-101. (doi: 10.1007/s00280-003-0721-x)

Cassidy, J. (2004) Phase I trials in oncology: design and endpoints. In: Figg, W.D. and McLeod, H.L. (eds.) Handbook of Anticancer Pharmacokinetics and Pharmacodynamics. Series: Cancer drug discovery and development. Humana Press: Totowa, NJ, USA, pp. 75-80. ISBN 9781588291776

Petty, R. and Cassidy, J. (2004) Novel fluoropyrimidines: Improving the efficacy and tolerability of cytotoxic therapy. Current Cancer Drug Targets, 4(2), pp. 191-204. (doi: 10.2174/1568009043481533)

Wang, W., Cassidy, J., O'Brien, V., Ryan, K. and Collie-Duguid, E. (2004) Mechanistic and Predictive Profiling of 5-Fluorouracil Resistance in Human Cancer Cells. Cancer Research, 64(22), pp. 8167-8176. (doi: 10.1158/0008-5472.CAN-04-0970)

2003

Scheithauer, W. et al. (2003) Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Annals of Oncology, 14(12), pp. 1735-1743. (doi: 10.1093/annonc/mdg500)

Cassidy, J. and Hochster, M. (2003) New oxaliplatin-based combinations in the treatment of colorectal cancer. Colorectal Disease, 5(S3), pp. 1-9. (doi: 10.1046/j.1463-1318.5.s3.2.x)

Piccart, M. et al. (2003) Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. International Journal of Gynecological Cancer, 13(s2), pp. 144-148. (doi: 10.1111/j.1525-1438.2003.13357.x)

Wang, W., McLeod, H. and Cassidy, J. (2003) Disulfiram-mediated inhibition of NF-kappa B activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. International Journal of Cancer, 104(4), pp. 504-511. (doi: 10.1002/ijc.10972)

Wang, W. and Cassidy, J. (2003) Constitutive nuclear factor-kappa B mRNA, protein overexpression and enhanced DNA-binding activity in thymidylate synthase inhibitor-resistant tumour cells. British Journal of Cancer, 88(4), pp. 624-629. (doi: 10.1038/sj.bjc.6600753)

Scott, L., Fraser, J. and Cassidy, J. (2003) Emerging drugs in colorectal cancer. Expert Opinion in Emerging Drugs, 8(1), pp. 193-202. (doi: 10.1517/14728214.8.1.193)

2002

Wang, W., Collie-Duguid, E. and Cassidy, J. (2002) Cerivastatin enhances the cytotoxicity of 5-fluorouracil on chemosensitive and resistant colorectal cancer cell lines. FEBS Letters, 531(3), pp. 415-420. (doi: 10.1016/S0014-5793(02)03575-5)

Boonsong, A., Curran, S., McKay, J., Cassidy, J., Murray, G. and McLeod, H. (2002) Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases. Human Pathology, 33(11), pp. 1114-1119. (doi: 10.1053/hupa.2002.129202)

Calvert, H., Jodrell, D., Cassidy, J. and Harris, A. (2002) Efficacy, safety, and cost of new anticancer drugs - Pessimistic conclusion was not justified. British Medical Journal, 325(7375), pp. 1302-1303. (doi: 10.1136/bmj.325.7375.1302/a)

Cassidy, J. and Misset, J. (2002) Oxaliplatin-related side effects: Characteristics and management. Seminars in Oncology, 29(5), pp. 11-20. (doi: 10.1053/sonc.2002.35524)

Campbell, N., Elliott, A., Sharp, L., Ritchie, L., Cassidy, J. and Little, J. (2002) Impact of deprivation and rural residence on treatment of colorectal and lung cancer. British Journal of Cancer, 87(6), pp. 585-590. (doi: 10.1038/sj.bjc.6600515)

Bain, N., Campbell, N., Ritchie, L. and Cassidy, J. (2002) Striking the right balance in colorectal cancer care - a qualitative study of rural and urban patients. Family Practice, 19(4), pp. 369-374. (doi: 10.1093/fampra/19.4.369)

Cassidy, J., Bridgewater, J., Mainwaring, P., Steward, W. and Wasan, H. (2002) Is the NICE process flawed? Lancet, 359(9323), pp. 2119-2120. (doi: 10.1016/S0140-6736(02)08932-8)

Twelves, C. and Cassidy, J. (2002) Which endpoints should we use in evaluating the use of novel fluoropyrimidine regimens in colorectal cancer? British Journal of Cancer, 86(11), pp. 1670-1676. (doi: 10.1038/sj.bjc.6600341)

Cassidy, J. et al. (2002) First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Annals of Oncology, 13(4), pp. 566-575. (doi: 10.1093/annonc/mdf089)

Diaz-Rubio, E., Evans, T. , Tabernero, J., Cassidy, J., Sastre, J., Eatock, M., Bisset, D., Regueiro, P. and Baselga, J. (2002) Capecitabine (Xeloda (R)) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors. Annals of Oncology, 13(4), pp. 558-565. (doi: 10.1093/annonc/mdf065)

Poole, C., Gardiner, J., Twelves, C., Johnston, P., Harper, P., Cassidy, J., Monkhouse, J., Banken, L., Weidekamm, E. and Reigner, B. (2002) Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients. Cancer Chemotherapy and Pharmacology, 49(3), pp. 225-234. (doi: 10.1007/s00280-001-0408-0)

Marsh, S., McKay, J., Curran, S., Murray, G., Cassidy, J. and McLeod, H. (2002) Primary colorectal tumour is not an accurate predictor of thymidylate synthase in lymph node metastasis. Oncology Reports, 9(2), pp. 231-234.

McKay, J., Douglas, J., Ross, V., Curran, S., Loane, J., Ahmed, F., Cassidy, J., McLeod, H. and Murray, G. (2002) Analysis of key cell-cycle checkpoint proteins in colorectal tumours. Journal of Pathology, 196(4), pp. 386-393. (doi: 10.1002/path.1053)

McKay, J., Loane, J., Ross, V., Ameyaw, M., Murray, G., Cassidy, J. and McLeod, H. (2002) c-erbB-2 is not a major factor in the development of colorectal cancer. British Journal of Cancer, 86(4), pp. 568-573. (doi: 10.1038/sj.bjc.6600127)

McKay, J., Murray, L., Curran, S., Ross, V., Clark, C., Murray, G., Cassidy, J. and McLeod, H. (2002) Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. European Journal of Cancer, 38(17), pp. 2258-2264. (doi: 10.1016/S0959-8049(02)00234-4)

2001

Rooney, P., Boonsong, A., McKay, J., Marsh, S., Stevenson, D., Murray, G., Curran, S., Haites, N., Cassidy, J. and McLeod, H. (2001) Colorectal cancer genomics: evidence for multiple genotypes which influence survival. British Journal of Cancer, 85(10), pp. 1492-1498. (doi: 10.1054/bjoc.2001.2095)

Van Cutsem, E. et al. (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. Journal of Clinical Oncology, 19(21), pp. 4097-4106.

Wang, W., Marsh, S., Cassidy, J. and McLeod, H. (2001) Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors. Cancer Research, 61(14), pp. 5505-5510.

Cassidy, J. (2001) Xeloda (R) in colorectal cancer. International Journal of Clinical Practice, 55(5), pp. 326-328.

Bissett, D., McLeod, H., Sheedy, B., Collier, M., Pithavala, Y., Paradiso, L., Pitsiladis, M. and Cassidy, J. (2001) Phase I dose-escalation and pharmacokinetic study of a novel folate analogue AG2034. British Journal of Cancer, 84(3), pp. 308-312. (doi: 10.1054/bjoc.2000.1601)

Campbell, N., Elliott, A., Sharp, L., Ritchie, L., Cassidy, J. and Little, J. (2001) Rural and urban differences in stage at diagnosis of colorectal and lung cancers. British Journal of Cancer, 84(7), pp. 910-914. (doi: 10.1054/bjoc.2000.1708)

Collie-Duguid, E., Johnston, S., Boyce, L., Smith, N., Cowieson, A., Cassidy, J., Murray, G. and McLeod, H. (2001) Thymidine phosphorylase and dihydropyrimidine dehydrogenase protein expression in colorectal cancer. International Journal of Cancer, 94(2), pp. 297-301. (doi: 10.1002/ijc.1462)

Ferguson, M., Ahmed, F. and Cassidy, J. (2001) The role of pro-drug therapy in the treatment of cancer. Drug Resistance Updates, 4(4), pp. 225-232. (doi: 10.1054/drup.2001.0207)

Hoff, P., Cassidy, J. and Schmoll, H. (2001) The evolution of fluoropyrimidine therapy: From intravenous to oral. Oncologist, 6(Suppl.), pp. 3-11. (doi: 10.1634/theoncologist.6-suppl_4-3)

Marsh, S., McKay, J., Cassidy, J. and McLeod, H. (2001) Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. International Journal of Oncology, 19(2), pp. 383-386.

Schellens, J. et al. (2001) Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9. Anti-Cancer Drugs, 12(7), pp. 583-590. (doi: 10.1097/00001813-200108000-00004)

Schmoll, H. and Cassidy, J. (2001) Integrating oxaliplatin into the management of colorectal cancer. Oncologist, 6(Suppl.), pp. 24-28. (doi: 10.1634/theoncologist.6-suppl_4-24)

Twelves, C., Boyer, M., Findlay, M., Cassidy, J., Weitzel, C., Baker, C., Osterwalder, B., Jamieson, C. and Hieke, K. (2001) Capecitabine (Xeloda (TM)) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. European Journal of Cancer, 37(5), pp. 597-604. (doi: 10.1016/S0959-8049(00)00444-5)

This list was generated on Tue Sep 15 20:30:59 2020 BST.
Number of items: 123.

Articles

Iveson, T. et al. (2019) 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT. Health Technology Assessment, 23(64), (doi: 10.3310/hta23640) (PMID:31852579)

Robles-Zurita, J. A. et al. (2018) SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer. British Journal of Cancer, 119(11), pp. 1332-1338. (doi: 10.1038/s41416-018-0319-z) (PMID:30420616) (PMCID:PMC6265336)

Iveson, T. J. et al. (2018) 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. Lancet Oncology, 19(4), pp. 562-578. (doi: 10.1016/S1470-2045(18)30093-7) (PMID:29611518) (PMCID:PMC5883334)

Graham, J., Spiliopoulou, P., Arbuckle, R., Bridge, J. A. and Cassidy, J. (2017) A pilot study of subjective well-being in colorectal cancer patients and their caregivers. Patient Related Outcome Measures, 8, pp. 111-119. (doi: 10.2147/PROM.S141815) (PMID:29089790) (PMCID:PMC5656346)

O’Neill, H.L., Cassidy, A.P., Harris, O.B. and Cassidy, J.W. (2016) BMP2/BMPR1A is linked to tumour progression in dedifferentiated liposarcomas. PeerJ, 4, e1957. (doi: 10.7717/peerj.1957) (PMID:27114889) (PMCID:PMC4841227)

Hickish, T. et al. (2014) A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer. European Journal of Cancer, 50(18), pp. 3136-3144. (doi: 10.1016/j.ejca.2014.08.008) (PMID:25441408)

Chu, E., Haller, D., Cartwright, T., Twelves, C., Cassidy, J., Sun, W., Saif, M.W., McKenna, E., Lee, S. and Schmoll, H.-J. (2014) Epidemiology and natural history of central venous access device use and infusion pump function in the NO16966 trial. British Journal of Cancer, 110(6), pp. 1438-1445. (doi: 10.1038/bjc.2014.74)

Steele, N., Anthony, A., Saunders, M., Esmarck, B., Ehrnrooth, E., Kristjansen, P.E.G., Nihlén, A., Hansen, L.T. and Cassidy, J. (2012) A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer. British Journal of Cancer, 106(5), pp. 793-798. (doi: 10.1038/bjc.2011.599)

Graham, J.S. and Cassidy, J. (2012) Adjuvant therapy in colon cancer. Expert Review of Anticancer Therapy, 12(1), pp. 99-109. (doi: 10.1586/era.11.189)

Samol, J., Ranson, M., Scott, E., Macpherson, E., Carmichael, J., Thomas, A. and Cassidy, J. (2012) Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study. Investigational New Drugs, 30(4), pp. 1493-1500. (doi: 10.1007/s10637-011-9682-9)

Paul, J. , Iveson, T., Midgely, R., Harkin, A., Masterton, M., Alexander, L. and Cassidy, J. (2011) Choice of randomisation time-point in non-inferiority studies of reduced treatment duration: experience from the SCOT study. Trials, 12(Sup.1), A30. (doi: 10.1186/1745-6215-12-S1-A30)

Cassidy, J. (2011) Guidelines for adjuvant therapy in colorectal cancer. Are they useful? And to whom? Clinical Oncology, 23(5), pp. 312-313. (doi: 10.1016/j.clon.2010.06.001)

Miles, D., Harbeck, N., Escudier, B., Hurwitz, H., Saltz, L., Van Cutsem, E., Cassidy, J., Mueller, B. and Sirzen, F. (2011) Disease Course Patterns After Discontinuation of Bevacizumab: Pooled Analysis of Randomized Phase III Trials. Journal of Clinical Oncology, 29(1), pp. 83-88. (doi: 10.1200/JCO.2010.30.2794)

Boyd, K.A. , Briggs, A. , Paul, J. , Iveson, T., Midgely, R., Harkin, A., Bates, G., Alexander, L. and Cassidy, J. (2011) Analysis of adverse events and quality of life data for an economic evaluation of adjuvant chemotherapy in colorectal cancer: when can we stop collecting? Trials, 12, A41. (doi: 10.1186/1745-6215-12-S1-A41)

Cassidy, J., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Rittweger, K., Gilberg, F. and Saltz, L. (2011) XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. British Journal of Cancer, 105(1), pp. 58-64. (doi: 10.1038/bjc.2011.201)

Cassidy, J., Saltz, L., Twelves, C., Van Cutsem, E., Hoff, P., Kang, Y., Saini, J.P., Gilberg, F. and Cunningham, D. (2011) Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients. Annals of Oncology, 22(12), pp. 2604-2609. (doi: 10.1093/annonc/mdr031)

Graham, J., Cassidy, J., Hughes, D. and Duerden, M. (2011) Ring-fencing a budget for cancer drugs: is it fair? Journal of the Royal College of Physicians of Edinburgh, 41(3), pp. 224-228. (doi: 10.4997/JRCPE.2011.310)

Lindsay, C.R. and Cassidy, J. (2011) XELOX in colorectal cancer: a convenient option for the future? Expert Review of Gastroenterology and Hepatology, 5(1), pp. 9-19. (doi: 10.1586/egh.10.90)

Yip, N. C., Fombon, I. S., Liu, P., Brown, S., Kannappan, V., Armesilla, A. L., Xu, B., Cassidy, J., Darling, J. L. and Wang, W. (2011) Disulfiram modulated ROS–MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties. British Journal of Cancer, 104(10), pp. 1564-1574. (doi: 10.1038/bjc.2011.126)

Douillard, J.-Y. et al. (2010) Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study. Journal of Clinical Oncology, 28(31), pp. 4697-4705. (doi: 10.1200/JCO.2009.27.4860)

Xu, B., Guo, X., Mathew, S., Armesilla, A. L., Cassidy, J., Darling, J. L. and Wang, W. (2010) Triptolide simultaneously induces reactive oxygen species, inhibits NF-κB activity and sensitizes 5-fluorouracil in colorectal cancer cell lines. Cancer Letters, 291(2), pp. 200-208. (doi: 10.1016/j.canlet.2009.10.013)

Cassidy, J., Saltz, L. B., Giantonio, B. J., Kabbinavar, F. F., Hurwitz, H. I. and Rohr, U.-P. (2010) Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. Journal of Cancer Research and Clinical Oncology, 136(5), pp. 737-743. (doi: 10.1007/s00432-009-0712-3)

Walker, J., Cassidy, J. and Sharpe, M. (2009) The third Symptom Management Research Trial in Oncology (SMaRT Oncology-3): a randomised trial to determine the efficacy of adding a complex intervention for major depressive disorder (Depression Care for People with Lung Cancer) to usual care, compared to usual care alone in patients with lung cancer. Trials, 10(1), p. 92. (doi: 10.1186/1745-6215-10-92)

Okines, A., del Puerto, O., Cunningham, D., Chau, I., Van Cutsem, E., Saltz, L. and Cassidy, J. (2009) Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. British Journal of Cancer, 101(7), pp. 1033-1038. (doi: 10.1038/sj.bjc.6605259)

Scott, L., Evans, T., Cassidy, J., Harden, S., Paul, J., Ullah, R., O'Brien, V. and Brown, R. (2009) Cytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour response. British Journal of Cancer, 101(3), pp. 410-417. (doi: 10.1038/sj.bjc.6605175)

Seymour, L. et al. (2009) Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. International Journal of Oncology, 34(6), pp. 1629-1636. (doi: 10.3892/ijo_00000293)

Lindsay, C.R., MacPherson, I.R.J. and Cassidy, J. (2009) Current status of cediranib: the rapid development of a novel anti-angiogenic therapy. Future Oncology, 5(4), pp. 421-432. (doi: 10.2217/FON.09.18)

Hénin, E. et al. (2009) A Dynamic Model of Hand-and-Foot Syndrome in Patients Receiving Capecitabine. Clinical Pharmacology and Therapeutics, 85(4), pp. 418-425. (doi: 10.1038/clpt.2008.220)

Cunningham, D. et al. (2009) Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. Annals of Oncology, 20(2), pp. 244-250. (doi: 10.1093/annonc/mdn638)

Walker, J., Cassidy, J. and Sharpe, M. (2009) The second Symptom Management Research Trial in Oncology (SMaRT Oncology-2): a randomised trial to determine the effectiveness and cost-effectiveness of adding a complex intervention for major depressive disorder to usual care for cancer patients. Trials, 10, p. 18. (doi: 10.1186/1745-6215-10-18)

Arkenau, H.-T. et al. (2008) Efficacy of Oxaliplatin Plus Capecitabine or Infusional Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Randomized Trials. Journal of Clinical Oncology, 26(36), pp. 5910-5917. (doi: 10.1200/JCO.2008.16.7759)

Graham, J., Plummer, R., Mccoy, C., Kowal, K., Wiesinger, H., Detjen, K., Calvert, H., Wiedenmann, B. and Cassidy, J. (2008) Open-label, non-randomised, inter-individual dose escalation of ZK 304709 with the evaluation of safety, tolerability, pharmacokinetics, oral bioavailability and orientating efficacy after daily administration in patients with advanced cancer (7 d treatment and 14 d recovery). European Journal of Cancer, 44(15), pp. 2162-2168. (doi: 10.1016/j.ejca.2008.06.006)

Cassidy, J. (2008) Radio-chemotherapy in rectal cancer. European Journal of Cancer, 44(12), pp. 1620-1621. (doi: 10.1016/j.ejca.2008.06.002)

Cassidy, J. (2008) Cetuximab for the treatment of patients with colorectal cancer. Nature Clinical Practice Oncology, 5(6), pp. 310-311. (doi: 10.1038/ncponc1130)

Cassidy, J., Schmoll, H. and Van Cutsem, E. (2008) Pharmacoeconomic benefits of capecitabine-based chemotherapy in metastatic colorectal cancer. Journal of Clinical Oncology, 26(13), pp. 226-227. (doi: 10.1200/JCO.2008.16.4244)

Haller, D. G. et al. (2008) Potential Regional Differences for the Tolerability Profiles of Fluoropyrimidines. Journal of Clinical Oncology, 26(13), pp. 2118-2123. (doi: 10.1200/JCO.2007.15.2090)

Glen, H. and Cassidy, J. (2008) Redefining adjuvant chemotherapy in patients with stage III colon cancer: X-ACT trial. Expert Review of Anticancer Therapy, 8(4), pp. 547-551. (doi: 10.1586/14737140.8.4.547)

Saltz, L. B. et al. (2008) Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study. Journal of Clinical Oncology, 26(12), pp. 2013-2019. (doi: 10.1200/JCO.2007.14.9930)

Cassidy, J. et al. (2008) Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer. Journal of Clinical Oncology, 26(12), pp. 2006-2012. (doi: 10.1200/JCO.2007.14.9898)

Sharp, L., Little, J., Brockton, N., Cotton, S., Masson, L., Haites, N. and Cassidy, J. (2008) Polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene, intakes of folate and related B vitamins and colorectal cancer: a case-control study in a population with relatively low folate intake. British Journal of Nutrition, 99(2), pp. 379-389. (doi: 10.1017/S0007114507801073)

Espie, C., Fleming, L., Cassidy, J., Samuel, L., Taylor, L., White, C., Douglas, N., Engleman, H., Kelly, H. and Paul, J. (2008) Randomized controlled clinical effectiveness trial of cognitive behavior therapy compared with treatment as usual for persistent insomnia in patients with cancer. Journal of Clinical Oncology, 26(28), pp. 4651-4658. (doi: 10.1200/JCO.2007.13.9006)

Guo, X., Goessl, E., Collie-Duguid, E., Cassidy, J., Wang, W. and O'Brien, V. (2008) Cell cycle perturbation and acquired 5-fluorouracil chemoresistance. Anticancer Research, 28(1A), pp. 9-14.

MacPherson, I. and Cassidy, J. (2008) Challenges in combinational oncology studies. Pharmaceutical Medicine, 22(2), pp. 85-97.

Cassidy, J. (2007) Capecitabine plus oxaliplatin in metastatic colorectal cancer. Journal of Clinical Oncology, 25(31), pp. 5043-5045. (doi: 10.1200/JCO.2007.13.4676)

Guo, X., Evans, T.R.J. , Somanath, S., Armesilla, A.L., Darling, J.L., Schatzlein, A., Cassidy, J. and Wang, W. (2007) In vitro evaluation of cancer-specific NF-kappaB-CEA enhancer-promoter system for 5-fluorouracil prodrug gene therapy in colon cancer cell lines. British Journal of Cancer, 97(6), pp. 745-754. (doi: 10.1038/sj.bjc.6603930)

MacLeod, A., Branch, A., Cassidy, J., McDonald, A., Mohammed, N. and Macdonald, L. (2007) A nurse-/pharmacy-led capecitabine clinic for colorectal cancer: results of a prospective audit and retrospective survey of patient experiences. European Journal of Oncology Nursing, 11(3), pp. 247-254. (doi: 10.1016/j.ejon.2006.10.001)

Kelly, C. and Cassidy, J. (2007) Capecitabine in the treatment of colorectal cancer. Expert Review of Anticancer Therapy, 7(6), pp. 803-810. (doi: 10.1586/14737140.7.6.803)

Wang, W., McLeod, H., Cassidy, J. and Collie-Duguid, E. (2007) Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks. Cancer Chemotherapy and Pharmacology, 59(6), pp. 839-845. (doi: 10.1007/s00280-006-0384-5)

Cassidy, J. (2007) Which first-line treatment is superior in advanced colorectal cancer: XELOX or pviFOX? Nature Clinical Practice Oncology, 4(5), pp. 280-281. (doi: 10.1038/ncponc0792)

Kelly, C. and Cassidy, J. (2007) Chemotherapy in metastatic colorectal cancer. Surgical Oncology, 16(1), pp. 65-70. (doi: 10.1016/j.suronc.2007.04.006)

Benson, C. et al. (2007) A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. British Journal of Cancer, 96(1), pp. 29-37. (doi: 10.1038/sj.bjc.6603509)

Hanauske, A., Cassidy, J., Sastre, J., Bolling, C., Jones, R. , Rakhit, A., Fettner, S., Brennscheidt, U., Feyereislova, A. and Diaz-Rubio, E. (2007) Phase 1b dose escalation study of erlotinib in combination with infusional 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors. Clinical Cancer Research, 13(2), pp. 523-531. (doi: 10.1158/1078-0432.CCR-06-1627)

Cassidy, J. (2007) Is breast cancer advocacy distorting the cancer budget to the disadvantage of other tumours? Breast Cancer Research, 9(Suppl.), S6. (doi: 10.1186/bcr1804)

Cassidy, J. (2007) Why patient representation might harm science? Breast Cancer Research, 9(Suppl.), S4. (doi: 10.1186/bcr1802)

Cassidy, J. (2006) The bottom line. European Journal of Cancer, 42(17), p. 2859.

Cassidy, J. (2006) Did you skip the lectures? European Journal of Cancer, 42(17), pp. 2860-2867. (doi: 10.1016/j.ejca.2006.07.010)

Cassidy, J. (2006) In response to: 'On prejudice and facts and choices', an editorial by Kohne and Folprecht. Annals of Oncology, 17(9), pp. 1469-1471. (doi: 10.1093/annonc/mdl082)

Robinson, H., Jones, R., Walker, M., Zachos, G., Brown, R., Cassidy, J. and Gillespie, D. (2006) Chk1-dependent slowing of S-phase progression protects DT40 B-lymphoma cells against killing by the nucleoside analogue 5-fluorouracil. Oncogene, 25(39), pp. 5359-5369. (doi: 10.1038/sj.onc.1209532)

Cassidy, J. et al. (2006) Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. British Journal of Cancer, 94(8), pp. 1122-1129. (doi: 10.1038/sj.bjc.6603059)

Chong, G. et al. (2006) Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer. Annals of Oncology, 17(3), pp. 437-442. (doi: 10.1093/annonc/mdj090)

Glen, H. and Cassidy, J. (2006) Vitamin D (and its analogs) in the treatment and prevention of cancer. Expert Review of Anticancer Therapy, 6(3), pp. 305-308. (doi: 10.1586/14737140.6.3.305)

Rustin, G. et al. (2006) Comparison of CA-125 and Standard Definitions of Progression of Ovarian Cancer in the Intergroup Trial of Cisplatin and Paclitaxel Versus Cisplatin and Cyclophosphamide. Journal of Clinical Oncology, 24(1), pp. 45-51. (doi: 10.1200/jco.2005.01.2757)

Nikolic-Tomasevic, Z., Jelic, S., Cassidy, J., Filipovic-Ljeskovic, I. and Tomasevic, Z. (2005) Fluoropyrimidine therapy: hyperbilirubinemia as a consequence of hemolysis. Cancer Chemotherapy and Pharmacology, 56(6), pp. 594-602. (doi: 10.1007/s00280-005-1011-6)

Boddy, A. et al. (2005) A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules. Clinical Cancer Research, 11(21), pp. 7834-7840. (doi: 10.1158/1078-0432.CCR-05-0803)

Beutel, G., Glen, H., Schoffski, P., Chick, J., Gill, S., Cassidy, J. and Twelves, C. (2005) Phase I study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors. Clinical Cancer Research, 11(15), pp. 5487-5495. (doi: 10.1158/1078-0432.CCR-05-0104)

Camidge, R., Reigner, B., Cassidy, J., Grange, S., Abt, M., Weidekamm, E. and Jodrell, D. (2005) Significant Effect of Capecitabine on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Cancer. Journal of Clinical Oncology, 23(21), pp. 4719-4725. (doi: 10.1200/JCO.2005.09.129)

Twelves, C. et al. (2005) Capecitabine/Oxaliplatin, a Safe and Active First-Line Regimen for Older Patients with Metastatic Colorectal Cancer: Post Hoc Analysis of a Large Phase II Study. Clinical Colorectal Cancer, 5(2), pp. 101-107. (doi: 10.3816/CCC.2005.n.021)

Twelves, C. et al. (2005) Capecitabine as adjuvant treatment for stage III colon cancer. New England Journal of Medicine, 352(26), pp. 2696-2704. (doi: 10.1056/NEJMoa043116)

Nurgat, Z., Craig, W., Campbell, N., Bissett, J., Cassidy, J. and Nicolson, M. (2005) Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy. British Journal of Cancer, 92(6), pp. 1001-1005. (doi: 10.1038/sj.bjc.6602423)

Mano, M., Cassidy, J. and Canney, P. (2005) Liver metastases from breast cancer: management of patients with significant liver dysfunction. Cancer Treatment Reviews, 31(1), pp. 35-48. (doi: 10.1016/j.ctrv.2004.09.007)

Eatock, M., Cassidy, J., Johnson, J., Morrison, R., Devlin, M., Blackey, R., Owen, S., Choi, R. and Twelves, C. (2005) A dose finding and pharmacokinetic study of the matrix metalloproteinase inhibitor MM1270 (previously termed CGS27023A) with 5-FU and folinic acid. Cancer Chemotherapy and Pharmacology, 55(1), pp. 39-46. (doi: 10.1007/s00280-004-0856-4)

Cassidy, J. (2005) Benefits and drawbacks of the use of oral fluoropyrimidines as single-agent therapy in advanced colorectal cancer. Clinical Colorectal Cancer, 5(Suppl), S47-S50. (doi: 10.3816/CCC.2005.s.007)

Waterston, A. and Cassidy, J. (2005) Adjuvant treatment strategies for early colon cancer. Drugs, 65(14), pp. 1935-1947. (doi: 10.2165/00003495-200565140-00003)

Rooney, P., Boonsong, A., McFadyen, M., McLeod, H., Cassidy, J., Curran, S. and Murray, G. (2004) The candidate oncogene ZNF217 is frequently amplified in colon cancer. Journal of Pathology, 204(3), pp. 282-288. (doi: 10.1002/path.1632)

Cassidy, J. and Schõtzlein, A. (2004) Tumour targeted drug and gene delivery: principles and concepts. Expert Reviews in Molecular Medicine, 6(19), pp. 1-17. (doi: 10.1017/S1462399404008269)

Bissett, D. et al. (2004) Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT). British Journal of Cancer, 91(1), pp. 50-55. (doi: 10.1038/sj.bjc.6601922)

Salazar, R., Bissett, D., Twelves, C., Breimer, L., Demario, M., Campbell, S., Zhi, J., Ritland, S. and Cassidy, J. (2004) A phase I clinical and pharmacokinetic study of Ro 31-7453 given as a 7- or 14-day oral twice daily schedule every 4 weeks in patients with solid tumors. Clinical Cancer Research, 10(13), pp. 4374-4382. (doi: 10.1158/1078-0432.CCR-04-0135)

Cassidy, J. et al. (2004) XELOX (capecitabine plus oxaliplatin): Active first-line therapy for patients with metastatic colorectal cancer. Journal of Clinical Oncology, 22(11), pp. 2084-2091. (doi: 10.1200/JCO.2004.11.069)

Robertson, R., Campbell, N., Smith, S., Donnan, P., Sullivan, F., Duffy, R., Ritchie, L., Millar, D., Cassidy, J. and Munro, A. (2004) Factors influencing time from presentation to treatment of colorectal and breast cancer in urban and rural areas. British Journal of Cancer, 90(8), pp. 1479-1485. (doi: 10.1038/sj.bjc.6601753)

Gourley, C., Cassidy, J., Edwards, C., Samuel, L., Bisset, D., Camboni, G., Young, A., Boyle, D. and Jodrell, D. (2004) A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer. Cancer Chemotherapy and Pharmacology, 53(2), pp. 95-101. (doi: 10.1007/s00280-003-0721-x)

Petty, R. and Cassidy, J. (2004) Novel fluoropyrimidines: Improving the efficacy and tolerability of cytotoxic therapy. Current Cancer Drug Targets, 4(2), pp. 191-204. (doi: 10.2174/1568009043481533)

Wang, W., Cassidy, J., O'Brien, V., Ryan, K. and Collie-Duguid, E. (2004) Mechanistic and Predictive Profiling of 5-Fluorouracil Resistance in Human Cancer Cells. Cancer Research, 64(22), pp. 8167-8176. (doi: 10.1158/0008-5472.CAN-04-0970)

Scheithauer, W. et al. (2003) Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Annals of Oncology, 14(12), pp. 1735-1743. (doi: 10.1093/annonc/mdg500)

Cassidy, J. and Hochster, M. (2003) New oxaliplatin-based combinations in the treatment of colorectal cancer. Colorectal Disease, 5(S3), pp. 1-9. (doi: 10.1046/j.1463-1318.5.s3.2.x)

Piccart, M. et al. (2003) Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. International Journal of Gynecological Cancer, 13(s2), pp. 144-148. (doi: 10.1111/j.1525-1438.2003.13357.x)

Wang, W., McLeod, H. and Cassidy, J. (2003) Disulfiram-mediated inhibition of NF-kappa B activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. International Journal of Cancer, 104(4), pp. 504-511. (doi: 10.1002/ijc.10972)

Wang, W. and Cassidy, J. (2003) Constitutive nuclear factor-kappa B mRNA, protein overexpression and enhanced DNA-binding activity in thymidylate synthase inhibitor-resistant tumour cells. British Journal of Cancer, 88(4), pp. 624-629. (doi: 10.1038/sj.bjc.6600753)

Scott, L., Fraser, J. and Cassidy, J. (2003) Emerging drugs in colorectal cancer. Expert Opinion in Emerging Drugs, 8(1), pp. 193-202. (doi: 10.1517/14728214.8.1.193)

Wang, W., Collie-Duguid, E. and Cassidy, J. (2002) Cerivastatin enhances the cytotoxicity of 5-fluorouracil on chemosensitive and resistant colorectal cancer cell lines. FEBS Letters, 531(3), pp. 415-420. (doi: 10.1016/S0014-5793(02)03575-5)

Boonsong, A., Curran, S., McKay, J., Cassidy, J., Murray, G. and McLeod, H. (2002) Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases. Human Pathology, 33(11), pp. 1114-1119. (doi: 10.1053/hupa.2002.129202)

Calvert, H., Jodrell, D., Cassidy, J. and Harris, A. (2002) Efficacy, safety, and cost of new anticancer drugs - Pessimistic conclusion was not justified. British Medical Journal, 325(7375), pp. 1302-1303. (doi: 10.1136/bmj.325.7375.1302/a)

Cassidy, J. and Misset, J. (2002) Oxaliplatin-related side effects: Characteristics and management. Seminars in Oncology, 29(5), pp. 11-20. (doi: 10.1053/sonc.2002.35524)

Campbell, N., Elliott, A., Sharp, L., Ritchie, L., Cassidy, J. and Little, J. (2002) Impact of deprivation and rural residence on treatment of colorectal and lung cancer. British Journal of Cancer, 87(6), pp. 585-590. (doi: 10.1038/sj.bjc.6600515)

Bain, N., Campbell, N., Ritchie, L. and Cassidy, J. (2002) Striking the right balance in colorectal cancer care - a qualitative study of rural and urban patients. Family Practice, 19(4), pp. 369-374. (doi: 10.1093/fampra/19.4.369)

Cassidy, J., Bridgewater, J., Mainwaring, P., Steward, W. and Wasan, H. (2002) Is the NICE process flawed? Lancet, 359(9323), pp. 2119-2120. (doi: 10.1016/S0140-6736(02)08932-8)

Twelves, C. and Cassidy, J. (2002) Which endpoints should we use in evaluating the use of novel fluoropyrimidine regimens in colorectal cancer? British Journal of Cancer, 86(11), pp. 1670-1676. (doi: 10.1038/sj.bjc.6600341)

Cassidy, J. et al. (2002) First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Annals of Oncology, 13(4), pp. 566-575. (doi: 10.1093/annonc/mdf089)

Diaz-Rubio, E., Evans, T. , Tabernero, J., Cassidy, J., Sastre, J., Eatock, M., Bisset, D., Regueiro, P. and Baselga, J. (2002) Capecitabine (Xeloda (R)) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors. Annals of Oncology, 13(4), pp. 558-565. (doi: 10.1093/annonc/mdf065)

Poole, C., Gardiner, J., Twelves, C., Johnston, P., Harper, P., Cassidy, J., Monkhouse, J., Banken, L., Weidekamm, E. and Reigner, B. (2002) Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients. Cancer Chemotherapy and Pharmacology, 49(3), pp. 225-234. (doi: 10.1007/s00280-001-0408-0)

Marsh, S., McKay, J., Curran, S., Murray, G., Cassidy, J. and McLeod, H. (2002) Primary colorectal tumour is not an accurate predictor of thymidylate synthase in lymph node metastasis. Oncology Reports, 9(2), pp. 231-234.

McKay, J., Douglas, J., Ross, V., Curran, S., Loane, J., Ahmed, F., Cassidy, J., McLeod, H. and Murray, G. (2002) Analysis of key cell-cycle checkpoint proteins in colorectal tumours. Journal of Pathology, 196(4), pp. 386-393. (doi: 10.1002/path.1053)

McKay, J., Loane, J., Ross, V., Ameyaw, M., Murray, G., Cassidy, J. and McLeod, H. (2002) c-erbB-2 is not a major factor in the development of colorectal cancer. British Journal of Cancer, 86(4), pp. 568-573. (doi: 10.1038/sj.bjc.6600127)

McKay, J., Murray, L., Curran, S., Ross, V., Clark, C., Murray, G., Cassidy, J. and McLeod, H. (2002) Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. European Journal of Cancer, 38(17), pp. 2258-2264. (doi: 10.1016/S0959-8049(02)00234-4)

Rooney, P., Boonsong, A., McKay, J., Marsh, S., Stevenson, D., Murray, G., Curran, S., Haites, N., Cassidy, J. and McLeod, H. (2001) Colorectal cancer genomics: evidence for multiple genotypes which influence survival. British Journal of Cancer, 85(10), pp. 1492-1498. (doi: 10.1054/bjoc.2001.2095)

Van Cutsem, E. et al. (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. Journal of Clinical Oncology, 19(21), pp. 4097-4106.

Wang, W., Marsh, S., Cassidy, J. and McLeod, H. (2001) Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors. Cancer Research, 61(14), pp. 5505-5510.

Cassidy, J. (2001) Xeloda (R) in colorectal cancer. International Journal of Clinical Practice, 55(5), pp. 326-328.

Bissett, D., McLeod, H., Sheedy, B., Collier, M., Pithavala, Y., Paradiso, L., Pitsiladis, M. and Cassidy, J. (2001) Phase I dose-escalation and pharmacokinetic study of a novel folate analogue AG2034. British Journal of Cancer, 84(3), pp. 308-312. (doi: 10.1054/bjoc.2000.1601)

Campbell, N., Elliott, A., Sharp, L., Ritchie, L., Cassidy, J. and Little, J. (2001) Rural and urban differences in stage at diagnosis of colorectal and lung cancers. British Journal of Cancer, 84(7), pp. 910-914. (doi: 10.1054/bjoc.2000.1708)

Collie-Duguid, E., Johnston, S., Boyce, L., Smith, N., Cowieson, A., Cassidy, J., Murray, G. and McLeod, H. (2001) Thymidine phosphorylase and dihydropyrimidine dehydrogenase protein expression in colorectal cancer. International Journal of Cancer, 94(2), pp. 297-301. (doi: 10.1002/ijc.1462)

Ferguson, M., Ahmed, F. and Cassidy, J. (2001) The role of pro-drug therapy in the treatment of cancer. Drug Resistance Updates, 4(4), pp. 225-232. (doi: 10.1054/drup.2001.0207)

Hoff, P., Cassidy, J. and Schmoll, H. (2001) The evolution of fluoropyrimidine therapy: From intravenous to oral. Oncologist, 6(Suppl.), pp. 3-11. (doi: 10.1634/theoncologist.6-suppl_4-3)

Marsh, S., McKay, J., Cassidy, J. and McLeod, H. (2001) Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. International Journal of Oncology, 19(2), pp. 383-386.

Schellens, J. et al. (2001) Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9. Anti-Cancer Drugs, 12(7), pp. 583-590. (doi: 10.1097/00001813-200108000-00004)

Schmoll, H. and Cassidy, J. (2001) Integrating oxaliplatin into the management of colorectal cancer. Oncologist, 6(Suppl.), pp. 24-28. (doi: 10.1634/theoncologist.6-suppl_4-24)

Twelves, C., Boyer, M., Findlay, M., Cassidy, J., Weitzel, C., Baker, C., Osterwalder, B., Jamieson, C. and Hieke, K. (2001) Capecitabine (Xeloda (TM)) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. European Journal of Cancer, 37(5), pp. 597-604. (doi: 10.1016/S0959-8049(00)00444-5)

Books

Cassidy, J., Johnston, P.G. and Van Cutsem, E. (2006) Colorectal Cancer. Taylor & Francis: Atlanta. ISBN 9780824728359

Book Sections

Glen, H. and Cassidy, J. (2013) Phase I Trials in Oncology: Design and Endpoint. In: Rudek, M. A., Chau, C. H., Figg, W. D. and McLeod, H. L. (eds.) Handbook of Anticancer Pharmacokinetics and Pharmacodynamics [2nd ed.]. Series: Cancer drug discovery and development. Springer, pp. 99-105. ISBN 9781461491347 (doi:10.1007/978-1-4614-9135-4_6)

Barrett, S.V. and Cassidy, J. (2007) Conventional chemotherapeutics. In: Alison, M.R. (ed.) The Cancer Handbook. John Wiley & Sons Ltd: Chichester, pp. 1191-1198. ISBN 9780470018521

Cassidy, J. (2005) Drug development and study design. In: Schellens, J.H.M., McLeod, H.L. and Newell, D.R. (eds.) Cancer Clinical Pharmacology. Oxford University Press: Oxford, UK, pp. 41-50. ISBN 9780192629661

Cassidy, J. (2004) Phase I trials in oncology: design and endpoints. In: Figg, W.D. and McLeod, H.L. (eds.) Handbook of Anticancer Pharmacokinetics and Pharmacodynamics. Series: Cancer drug discovery and development. Humana Press: Totowa, NJ, USA, pp. 75-80. ISBN 9781588291776

Edited Books

Cassidy, J., Bissett, D., Spence, R.A.J. and Payne, M. (Eds.) (2006) Oxford Handbook of Oncology. Series: Oxford medical publications. Oxford University Press: Oxford, UK. ISBN 9780198567875

Conference Proceedings

Paul, J. , Briggs, A. , Harking, A., Hayclon, M., Iveson, T., Masterson, M., Midgley, A. and Cassidy, J. (2006) SCOT: short course oncology therapy — a comparison of 12 and 24 weeks of adjuvant chemotherapy in colorectal cancer. In: 2011 ASCO Annual Meeting, Chicago, Ill, USA, 3-7 Jun 2011, e14145.

This list was generated on Tue Sep 15 20:30:59 2020 BST.

Research datasets

Jump to: 2019
Number of items: 1.

2019

Paul, J. , Boyd, K. , Briggs, A. , Cassidy, J., Harkin, A. and Iveson, T. (2019) The 'Short Course Oncology Treatment' (SCOT) trial. [Data Collection]

This list was generated on Sat Sep 25 10:34:07 2021 BST.